VANCOUVER, BC – Health Canada has issued a Notice of Compliance (NOC) to Cardiome Pharma for BRINAVESS® (vernakalant hydrochloride, IV), allowing the company to begin selling the drug in Canada.
BRINAVESS® is indicated for the rapid conversion of recent onset atrial fibrillation (AF) to sinus rhythm for non-surgery patients with AF less than or equal to seven days; and post-cardiac surgery patients with duration of AF less than or equal to three days.
“We are pleased and excited to have received the Notice of Compliance for BRINAVESS® from Health Canada,” commented company president and CEO William Hunter. He adds that this is a very proud moment for the company since BRINAVESS® was discovered in Canada by Canadian researchers who had the goal of making this drug available in their own backyard.
The company expects that its commercial team will begin detailing BRINAVESS® to potential hospital customers during the second quarter, positioning it for commercial sales beginning in the third quarter.